How U.S. vaccine recommendations compare with other countries and international organizations.
This framework describes how recommendations are categorized; it does not affect vaccine availability.
On January 5, 2026, the U.S. Department of Health and Human Services (HHS) reorganized the federal immunization schedule into a three-tier framework. This structure distinguishes between universal recommendations, risk-based recommendations, and shared clinical decision-making.
DTaP, Hib, PCV, Polio (IPV), MMR, HPV (1 dose), Varicella — covering 11 diseases.
RSV, Hepatitis A, Hepatitis B, Dengue, Meningococcal ACWY, Meningococcal B.
Rotavirus, COVID-19, Influenza, Meningococcal Disease, Hepatitis A, Hepatitis B.
Note: Meningococcal disease, Hepatitis A, and Hepatitis B are dually categorized (Tier 2 and Tier 3) depending on age, medical history, and exposure risk. For technical definitions of these tiers, see the Glossary.
This section analyzes how international health systems categorize vaccine priority relative to the U.S. model.
The NHS utilizes a centralized universal schedule. Unlike the U.S. Tier 3 model, the UK does not utilize a discretionary category for routine childhood vaccines. Since August 2017, the UK has included the Hepatitis B vaccine as part of the routine "6-in-1" infant series (Infanrix hexa) administered at 8, 12, and 16 weeks.
While the U.S. Tier 1 represents a federal "recommendation for all," several EU nations utilize legally enforced "mandatory" frameworks. For example, France mandates 11 vaccines and Italy mandates 10; non-compliance in these systems may result in fines or school exclusion. By contrast, U.S. Tier 1 remains a recommendation, with school-entry requirements set at the state level rather than by federal mandate.
Canada's National Advisory Committee on Immunization (NACI) utilizes specific recommendation grades. For certain vaccines like Meningococcal B, NACI may categorize the intervention as "discretionary" or "recommended on an individual basis," which aligns functionally with the U.S. framework of being recommended through shared clinical decision-making.
Clinical Context
While the U.S. relies on the FDA Biologics License Application (BLA) and ACIP recommendations to set tiers, peer nations utilize localized evidence reviews. The UK "Green Book" and Canada's "Immunization Guide" serve as the primary clinical authorities for these respective jurisdictions.
This section examines vaccines that have differing international classifications compared to the 2026 U.S. framework.
Currently recommended through shared clinical decision-making in the U.S. (Tier 3). It remains a universal recommendation in the UK (NHS), Australia (NIP), and most Canadian provinces.
The U.S. now categorizes the birth dose as Tier 2 (High-Risk). The World Health Organization (WHO), in its Hepatitis B Position Paper (WER No. 27, July 2017), continues to recommend a universal birth dose within 24 hours of life for all infants globally as part of the Expanded Programme on Immunization (EPI).
The U.S. recommendation through shared clinical decision-making (Tier 3) for the general pediatric population contrasts with the UK NHS, where the influenza vaccine is a universal annual recommendation for all school-aged children.
The following table compares the number of diseases targeted by universal or routine programs. Counts reflect diseases targeted by routine/universal programs; methodology and inclusion criteria vary by nation. The total count of antigens is an organizational metric and does not, by itself, determine the overall level of population-level disease protection.
| Country / Region | Diseases Covered | Framework |
|---|---|---|
| United States | 11 | Three-Tier Framework (Universal / Risk / SCDM) |
| United Kingdom | 13 | Centralized Universal Schedule |
| Australia | 13 | National Immunisation Program (NIP) |
| France | 11 | Mandatory National Framework |